VIVA-KKH Paediatric Brain and Solid Tumour Laboratory, KK Women's and Children's Hospital, Singapore.
Laboratory of Cancer Epigenome, National Cancer Centre, Singapore.
Histopathology. 2018 Jan;72(2):320-329. doi: 10.1111/his.13366. Epub 2017 Oct 30.
Clear cell sarcoma of the kidney (CCSK) is a rare paediatric renal malignant tumour. The majority of CCSKs have internal tandem duplications (ITDs) of the BCOR gene, whereas a minority have the YWHAE-NUTM2 gene fusion. A third 'double-negative' (DN) category comprises CCSKs with neither BCOR ITDs nor YWHAE-NUTM2 fusion. The aim of this study was to characterise 11 histologically diagnosed CCSKs immunohistochemically (with CCND1, BCOR and CCNB3 stains) and genetically.
By next-generation sequencing, 10 cases (90.9%) had BCOR exon 15 ITDs, with positive BCOR immunoreactivity being found in four (36%) or eight (72%) cases, depending on the antibody clone. By reverse transcription polymerase chain reaction, none had the YWHAE-NUTM2 fusion. The DN case had a BCOR-CCNB3 fusion and strong nuclear CCNB3 and BCOR immunoreactivity. Quantitative polymerase chain reaction showed markedly elevated BCOR expression in this case, whereas BCOR ITD cases had lower levels of elevated BCOR expression.
The majority of the CCSKs in our cohort had BCOR ITDs, and none had the YWHAE-NUTM2 fusion. We verified the strong, diffuse cyclin D1 (CCND1) immunoreactivity in CCSKs described in recent reports. BCOR immunoreactivity was not consistently positive in all CCSKs with BCOR ITDs, and therefore cannot be used as a diagnostic immunohistochemical stain to identify BCOR ITD cases. The DN case was a BCOR-CCNB3 fusion sarcoma. BCOR-CCNB3 sarcoma is typically a primary bone sarcoma affecting male adolescents, and this is the first report of it presenting in a kidney of a young child as a CCSK. The full spectrum of DN CCSKs awaits more comprehensive characterisation.
肾透明细胞肉瘤(CCSK)是一种罕见的小儿肾恶性肿瘤。大多数 CCSK 具有 BCOR 基因的内部串联重复(ITD),而少数具有 YWHAE-NUTM2 基因融合。第三种“双阴性”(DN)类别包括既没有 BCOR ITD 也没有 YWHAE-NUTM2 融合的 CCSK。本研究旨在通过免疫组织化学(用 CCND1、BCOR 和 CCNB3 染色)和遗传学方法对 11 例组织学诊断为 CCSK 的病例进行特征描述。
通过下一代测序,10 例(90.9%)病例存在 BCOR 外显子 15 ITD,根据抗体克隆,有 4 例(36%)或 8 例(72%)病例存在阳性 BCOR 免疫反应性。通过逆转录聚合酶链反应,没有 YWHAE-NUTM2 融合。DN 病例存在 BCOR-CCNB3 融合和强核 CCNB3 和 BCOR 免疫反应性。定量聚合酶链反应显示该病例 BCOR 表达明显升高,而 BCOR ITD 病例的 BCOR 表达升高水平较低。
我们队列中的大多数 CCSK 存在 BCOR ITD,并且没有 YWHAE-NUTM2 融合。我们验证了最近报道中描述的 CCSK 中强烈、弥漫性的 cyclin D1(CCND1)免疫反应性。并非所有存在 BCOR ITD 的 CCSK 中均存在阳性的 BCOR 免疫反应性,因此不能将其用作识别 BCOR ITD 病例的诊断性免疫组织化学染色。DN 病例为 BCOR-CCNB3 融合肉瘤。BCOR-CCNB3 肉瘤通常是一种影响男性青少年的原发性骨肉瘤,这是首例在小儿肾脏中表现为 CCSK 的病例。DN CCSK 的全貌有待更全面的特征描述。